4.0
24 Dec 2025
Former employee, more than 5 years
London, England
Recommend
CEO approval
Business outlook
Pros
- Great products, solid growth - Talented ExCo members - Global presence, values-led
Cons
- Weak scientific leadership and weak drug pipeline - Too many 'experts' being allowed to do whatever they want, no results - AI/ML function poorly led and has wasted 100's of millions in investment